GlassScriptPhysician profile
Reshma N Patel
NPI 1801058342
$825.77
in general payments reported to CMS, 2019-2025
15 companies · $415 in 2025
The $415 reported for 2025 was more than what 76% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $62.39 · 2020: $21.30 · 2022: $101 · 2023: $32.01 · 2024: $194 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $477 · Entertainment: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $477.15 |
| Entertainment | $163.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optos, INC. | $163.93 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Biogen, INC. | $151.29 | 2025 | Zurzuvae |
| Shield Therapeutics INC | $132.13 | 2024 | |
| Organon LLC | $70.42 | 2025 | Nexplanon |
| Lupin INC. | $48.42 | 2019 | |
| Abbvie INC. | $38.63 | 2022 | |
| Vertical Pharmaceuticals, LLC | $35.27 | 2019-2020 | |
| Exeltis, USA INC. | $31.66 | 2022-2023 | Slynd |
| Mayne Pharma Commercial LLC | $29.58 | 2025 | |
| Merck Sharp & Dohme LLC | $28.42 | 2024 | Gardasil, Gardasil 9 |
| Bayer Healthcare Pharmaceuticals INC. | $22.53 | 2022 | |
| Myovant Sciences INC. | $22.17 | 2022 | |
| Minerva Surgical, INC | $19.53 | 2024 | |
| Sumitomo Pharma America, INC. | $18.02 | 2023 | Myfembree |
| Coopersurgical, INC. | $13.77 | 2024 | Summit Doppler |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reshma Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.